These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12584167)

  • 1. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
    House MG; Guo M; Iacobuzio-Donahue C; Herman JG
    Carcinogenesis; 2003 Feb; 24(2):193-8. PubMed ID: 12584167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms.
    Yoshida K; Nagasaka T; Umeda Y; Tanaka T; Kimura K; Taniguchi F; Fuji T; Shigeyasu K; Mori Y; Yanai H; Yagi T; Goel A; Fujiwara T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1557-69. PubMed ID: 27095449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
    Sato N; Ueki T; Fukushima N; Iacobuzio-Donahue CA; Yeo CJ; Cameron JL; Hruban RH; Goggins M
    Gastroenterology; 2002 Jul; 123(1):365-72. PubMed ID: 12105864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice.
    Yamaguchi J; Mino-Kenudson M; Liss AS; Chowdhury S; Wang TC; Fernández-Del Castillo C; Lillemoe KD; Warshaw AL; Thayer SP
    Gastroenterology; 2016 Dec; 151(6):1232-1244.e10. PubMed ID: 27523981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas.
    Hong SM; Omura N; Vincent A; Li A; Knight S; Yu J; Hruban RH; Goggins M
    Clin Cancer Res; 2012 Feb; 18(3):700-12. PubMed ID: 22173550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of secreted apoptosis-related protein 2 (SARP2) in pure pancreatic juice in diagnosis of pancreatic neoplasms.
    Watanabe H; Okada G; Ohtsubo K; Yao F; Jiang PH; Mouri H; Wakabayashi T; Sawabu N
    Pancreas; 2006 May; 32(4):382-9. PubMed ID: 16670620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locus/chromosome aberrations in intraductal papillary mucinous neoplasms analyzed by fluorescence in situ hybridization.
    Miyabe K; Hori Y; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Yoshida M; Umemura S; Kato A; Ohara H; Joh T; Inagaki H
    Am J Surg Pathol; 2015 Apr; 39(4):512-20. PubMed ID: 25517961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.
    House MG; Herman JG; Guo MZ; Hooker CM; Schulick RD; Lillemoe KD; Cameron JL; Hruban RH; Maitra A; Yeo CJ
    Ann Surg; 2003 Sep; 238(3):423-31; discussion 431-2. PubMed ID: 14501508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Reprimo Down-regulation on Malignant Transformation of Intraductal Papillary Mucinous Neoplasm.
    Nakazato T; Suzuki Y; Tanaka R; Abe N; Masaki T; Mori T; Ohkura Y; Sugiyama M
    Pancreas; 2018 Mar; 47(3):291-295. PubMed ID: 29401170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas.
    Sato N; Goggins M
    J Hepatobiliary Pancreat Surg; 2006; 13(4):280-5. PubMed ID: 16858538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms.
    Chhoda A; Sharma A; Sailo B; Tang H; Ruzgar N; Tan WY; Ying L; Khatri R; Narayanan A; Mane S; De Kumar B; Wood LD; Iacobuzio-Donahue C; Wolfgang CL; Kunstman JW; Salem RR; Farrell JJ; Ahuja N
    Clin Epigenetics; 2023 Feb; 15(1):28. PubMed ID: 36803844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).
    Fujiyama Y; Kumamoto Y; Nishizawa N; Nakamoto S; Harada H; Yokota K; Tanaka Y; Igarashi K; Oiki H; Okuwaki K; Iwai T; Kajita S; Takahashi H; Tajima H; Kaizu T; Sasaki J; Watanabe M; Yamashita K
    Ann Surg Oncol; 2020 Oct; 27(10):4007-4016. PubMed ID: 32144623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas.
    Guo M; Jia Y; Yu Z; House MG; Esteller M; Brock MV; Herman JG
    Discov Med; 2014 Feb; 17(92):67-73. PubMed ID: 24534469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
    Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
    Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas.
    Miyasaka Y; Nagai E; Yamaguchi H; Fujii K; Inoue T; Ohuchida K; Yamada T; Mizumoto K; Tanaka M; Tsuneyoshi M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4371-7. PubMed ID: 17671118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.